All In Biotech

NDA 217338 · Reckitt Benckiser

Mucinex 12hr Cold & Fever Multi-Symptom

Dextromethorphan Hydrobromide, Guaifenesin, Naproxen Sodium · Oral · Expectorant

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Dec 22, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

206

29 Phase 3, 17 recruiting

FAERS reports

20,324

9,557 serious, 1,257 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2026.

Uses ■ helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive ■ temporarily relieves: ■ cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants ■ the intensity of coughing ■ the impulse to cough to help you get to sleep ■ minor aches and pains due to headache and the common cold ■ temporarily reduces fever

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM · DEXTROMETHORPHAN HYDROBROMIDE 30MG; GUAIFENESIN 600MG; NAPROXEN SODIUM 110MG · TABLET, EXTENDED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextromethorphan Hydrobromide" as an intervention, any sponsor and status, largest first.

All 206 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,745
  • dyspnoea1,634
  • fatigue1,350
  • nausea1,257
  • diarrhoea1,221
  • cough1,217
  • pneumonia1,166
  • headache1,103
  • dizziness1,006
  • pain844
  • sinusitis699
  • asthenia671

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200583
2006124
2007173
2008227
2009266
2010527
2011494
2012568
2013558
2014659
20151,486
20162,525
20171,592
20181,449
20191,457
20201,507
2021918
20221,112
20231,205
20241,296
20251,494
2026581

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 28 on PubMed

Sponsor: Reckitt Benckiser

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.